Lynozyfic-Linvoseltamab-Gcpt
Lynozyfic is a monotherapy for adults with relapsed and refractory multiple myeloma after ≥3 prior therapies. This bispecific T-cell engager bridges CD3 on T-cells with BCMA protein on myeloma cells to activate cancer-cell killing. FDA and EMA approved for heavily pretreated patients who have exhausted standard treatment options.
Zegfrovy-Sunvozertinib
Zegfrovy is a significant breakthrough in precision oncology for patients with non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertion mutations. It sets a new benchmark for patients with few therapy alternatives by combining clinically significant efficacy, oral convenience, and highly selective EGFR inhibition. Its quick approval highlights the critical need for efficient […]
Ibtrozi-Taletrectinib
Ibtrozi is a targeted oral therapy for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. This selective ROS1 tyrosine kinase inhibitor received FDA approval in June 2025 with breakthrough therapy designation. Features enhanced CNS penetration for improved efficacy against brain metastases compared to earlier ROS1 inhibitors.
Andembry-Garadacimab-Gxii
Andembry is a preventive therapy for hereditary angioedema (HAE) in adults and adolescents 12+ years. This selective Factor XIIa inhibitor targets the top of the inflammatory cascade with once-monthly dosing. FDA-approved in June 2025, offering the first monthly prophylactic HAE treatment targeting Factor XIIa.
Tryptyr-Acoltremon
Tryptyr is an oral neuroactive steroid modulator designed to treat dry eye disease. It acts on nervous system pathways to relieve symptoms and improve eye comfort.
Enflonsia-Clesrovimab-Cfor
ENFLONSIA is a long-acting, preventive monoclonal antibody developed to protect infants against a broad range of respiratory syncytial virus (RSV) disease severity. This includes severe cases that may lead to hospitalization. It is the first and only RSV preventive option that offers a weight-independent, single-dose administration, simplifying protection across all infants regardless of size or […]
Avmapki Fakzynja Co-Pack-Avutometinib And Defactinib
Avmapki Fakzynja combines two oral kinase inhibitors for adults with KRAS‑mutated recurrent low‑grade serous ovarian cancer after prior systemic therapy. It targets both MEK and FAK pathways to help control tumor growth in patients with limited treatment options.
Emrelis-Telisotuzumab Vedotin-Tllv
Emrelis is an antibody‑drug conjugate for adults with locally advanced or metastatic non-squamous non-small cell lung cancer overexpressing c‑Met after prior therapy. It delivers targeted chemotherapy directly to cancer cells to inhibit tumor progression.
Penpulimab-Kcqx-Penpulimab-Kcqx
Penpulimab‑Kcqx is an intravenous PD‑1 inhibitor used with chemotherapy to treat recurrent or metastatic non-keratinizing nasopharyngeal carcinoma. It boosts immune response to help control tumor growth in patients who have progressed after prior therapies.
Imaavy-Nipocalimab-Aahu
Imaavy is an IV antibody for adults and teens aged 12 and older with generalized myasthenia gravis who test positive for AChR or MuSK antibodies. It targets and blocks the FcRn receptor to reduce harmful autoantibodies and improve muscle strength.
